Overview

A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma

Status:
Unknown status

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

To determine the safety and efficacy of surgical resection with Gliadel® 3.85% wafer implantation, followed by concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab in subjects undergoing initial surgery for newly-diagnosed high grade glioma.

Phase:

Phase 2

Details

Lead Sponsor:

Kentuckiana Cancer Institute

Collaborator:

Eisai Inc.

Treatments:

Bevacizumab
Dacarbazine
Temozolomide